Press release
Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market
DelveInsight's "Osteosarcoma Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Othe steosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Osteosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Curious about the latest updates in the Osteosarcoma Pipeline? Click here to explore the therapies and trials making headlines @ Osteosarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Osteosarcoma Pipeline Report
* On 16 September 2025, Merck Sharp & Dohme LLC announced a study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
* DelveInsight's Osteosarcoma Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Osteosarcoma treatment.
* The leading Osteosarcoma Companies such as Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Promising Osteosarcoma Therapies such as Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.
Want to know which companies are leading innovation in Osteosarcoma? Dive into the full pipeline insights @ Osteosarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Osteosarcoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteosarcoma Pipeline Report also highlights the unmet needs with respect to the Osteosarcoma.
Osteosarcoma Overview
Osteosarcoma, also known as osteogenic sarcoma, is a rare type of bone cancer that originates in the bones, specifically affecting the long bones like those around the knee and shoulder. This cancer primarily develops in children and teenagers who are still growing. The exact cause of osteosarcoma is not fully understood, although in some instances, there is a familial predisposition with at least one gene associated with an increased risk. The hallmark symptom of osteosarcoma is pain, which can start intermittently but usually progresses to become constant.
Osteosarcoma Emerging Drugs Profile
* HS-20093: Hansoh BioMedical R&D Company
HS-20093 is a novel B7-H3-targeted antibody-drug conjugate that consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. This innovative drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, and other solid tumors through multiple phase I and II clinical trials in China. The mechanism of action (MOA) of HS-20093 involves the specific targeting of B7-H3, a transmembrane receptor highly prevalent on malignant cells, with the monoclonal antibody component. This targeting allows for the delivery of the topoisomerase inhibitor payload directly to the cancer cells, where it can exert its cytotoxic effects, potentially leading to tumor cell death and inhibition of tumor growth. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Osteosarcoma.
* ZN c3: Zentalis Pharmaceuticals
ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.
* NPX267: Nextpoint Therapeutics
NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers - a tumor antigen expressed independently of PD-L1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Osteosarcoma.
If you're tracking ongoing Osteosarcoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Osteosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteosarcoma Companies
Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
Osteosarcoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Osteosarcoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Osteosarcoma Pipeline Report covers it all - check it out now @ Osteosarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Osteosarcoma Pipeline Report
* Coverage- Global
* Osteosarcoma Companies- Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Osteosarcoma Therapies- Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.
* Osteosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Osteosarcoma Treatment landscape in this detailed analysis @ Osteosarcoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Osteosarcoma: Overview
* Osteosarcoma Pipeline Therapeutics
* Osteosarcoma Therapeutic Assessment
* Osteosarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HS-20093: Hansoh BioMedical R&D Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* NPX267: Nextpoint Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteosarcoma Key Companies
* Osteosarcoma Key Products
* Osteosarcoma- Unmet Needs
* Osteosarcoma- Market Drivers and Barriers
* Osteosarcoma- Future Perspectives and Conclusion
* Osteosarcoma Analyst Views
* Osteosarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteosarcoma-pipeline-insights-report-2025-by-delveinsight-mapping-innovative-rd-strategies-clinical-advancements-pharma-leadership-and-future-growth-potential-in-the-therapeutics-market]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
                     Copy
                  
                 Please set a link in the press area of your homepage to this press release on openPR.  openPR disclaims liability for any content contained in this release. 
    You can edit or delete your press release Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market here
News-ID: 4190578 • Views: …
More Releases from ABNewswire
 
                                            
                                                    Quest Auto Sales Transforms Used Cars for Sale Market with a Customer-First Fina …                                                
                                            
                                        
                                            Quest Auto Sales at 4501 L St, Omaha, offers flexible financing and transparent pricing on pre-owned vehicles, driving growth through customer referrals and personalized service in the local market.
The pre-owned vehicle market in Omaha is shifting as Quest Auto Sales [https://www.questautosales.com/] introduces a financing approach that prioritizes customer needs over rigid sales quotas. Located at 4501 L St in Omaha, NE 68117, the dealership has built its reputation on flexible…  
                                        
                                     
                                            
                                                    Crown Reconstruction Services Inc. Introduces Transparent Pricing Model for Roof …                                                
                                            
                                        
                                            Crown Reconstruction Services Inc. in Laguna Beach introduces itemized pricing for roofing projects, giving property owners detailed cost breakdowns before work begins.
A Laguna Beach-based contractor is addressing one of the construction industry's most persistent challenges: pricing transparency. Crown Reconstruction Services Inc. [https://crownreconstructionservices.com/], operating from its office at 2055 Laguna Canyon Rd, has implemented a new pricing structure that provides homeowners with detailed, itemized estimates before any work begins.
The roofing industry…  
                                        
                                     
                                            
                                                    Blue Ocean Life Brings Ocean-Inspired Calm, Resilience, and Freedom to Everyday  …                                                
                                            
                                        
                                            Blue Ocean Life Company LLC spreads a message of healing, balance, and coastal calm through its mission-driven apparel and lifestyle brand. With designs like "Saltwater Heals Everything" and "Find Your Calm," the Cape Cod-based company blends style with purpose, reminding people of the restorative power of the ocean while addressing rising mental health challenges through lifestyle design.
CAPE COD, Mass. - Blue Ocean Life Company LLC is spreading a message of…  
                                        
                                     
                                            
                                                    Third Hemisphere Strengthens Position as Leading Investment Communications Speci …                                                
                                            
                                        
                                            Jeremy Liddle [https://thirdhemisphere.agency/about-us] Third Hemisphere has established itself as a specialist in alternative investment communications, expanding capabilities across private credit, growth equity, and venture capital. The agency's regional positioning reflects the increasing sophistication of the Asia-Pacific investment landscape, where institutional allocators are diversifying beyond traditional public markets into private and alternative asset strategies.
The alternative investment environment in the region demands communications expertise that integrates financial understanding, Third Hemisphere, a full…  
                                        
                                    More Releases for Osteosarcoma
                                                    Osteosarcoma Drug Market Hits New High | Major Giants AstraZeneca,Pfizer,Amgen,                                                
                                            
                                        
                                            HTF MI just released the Global Osteosarcoma Drug Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Osteosarcoma Drug Market are: Pfizer, Amgen, Bayer,…  
                                        
                                    
                                                    Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuti …                                                
                                            
                                        
                                            The Osteosarcoma market growth is driven by factors like increase in the prevalence of Osteosarcoma, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Osteosarcoma market report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Osteosarcoma market size, share, Osteosarcoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteosarcoma market…  
                                        
                                    
                                                    Exploring the Osteosarcoma Drug Market: Trends, Opportunities, and Challenges                                                
                                            
                                        
                                            Osteosarcoma, a rare and aggressive bone cancer primarily affecting adolescents and young adults, has garnered significant attention in the pharmaceutical sector due to its complex treatment requirements and evolving drug landscape. This guest post delves into the osteosarcoma drug market, providing insights into its current state, opportunities, challenges, and future trends.
Introduction
Osteosarcoma is the most common primary malignant bone tumor, often occurring in the long bones of the arms and legs.…  
                                        
                                    
                                                    Osteosarcoma Market Size, Share, Trends & Forecast - 2034                                                
                                            
                                        
                                            Overview:
According to the IMARC Group, the osteosarcoma market exhibited a market size of US$ 880.9 Million in the year 2023 and is projected at a CAGR of 4.68% during 2024-2034. This can be attributed to the growing use of combination therapy involving neoadjuvant chemotherapy and surgical resection, which improves treatment outcomes in patients and reduces the risk of cancer relapse.
The osteosarcoma market report offers a comprehensive analysis of the market…  
                                        
                                    
                                                    Osteosarcoma Market Report 2023-2033 | Industry Size, Growth and Latest Insights                                                
                                            
                                        
                                            Market Overview:
The osteosarcoma market is expected to exhibit a CAGR of 4.87% during 2023-2033. The report offers a comprehensive analysis of the osteosarcoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally,…  
                                        
                                    
                                                    Pediatric Osteosarcoma Therapeutics Market Insights, Forecast to 2031                                                
                                            
                                        
                                            The report extensively examines the global Pediatric Osteosarcoma Therapeutics market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Pediatric Osteosarcoma Therapeutics. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global…  
                                        
                                    